Zh.V. Bryantseva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zh.V. Bryantseva has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Petr V. Krivorotko
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
10 shared publications - Sergey Nikolaevich Novikov
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
10 shared publications - Ирина Александровна Акулова
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
9 shared publications - Tengiz T. Tabagua
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
8 shared publications - Daria G. Ulrikh
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
5 shared publications - T. S. Yaganova
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
5 shared publications
Latest Publications
- 28 March 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (1)
Comparative Analysis of Oncological Efficacy and Cosmetic Outcomes of Accelerated Partial Breast Irradiation Techniques: Multicatheter Interstitial Brachytherapy and Conformal External Beam Radiotherapy
Accelerated partial breast irradiation (APBI) is a standard radiotherapy approach for patients with early-stage breast cancer. Various techniques can be employed to deliver APBI, with external beam radiotherapy (EBRT) and interstitial high-dose-rate brachytherapy (HDR-BT) using an Ir-192 source being the most commonly used in clinical practice. Purpose : To compare the oncological efficacy and cosmetic outcomes in breast cancer patients treated with postoperative APBI using either HDR-BT or EBRT. The primary efficacy endpoints were ipsilateral breast tumor recurrence-free survival (IBTR-FS) and recurrence-free survival (RFS). Materials and Methods : Between 2016 and 2022, 183 patients with рТ 1-2 N 0 M 0 breast cancer underwent APBI to the tumor bed after breast-conserving surgery. In the APBI-EBRT group (n = 85), irradiation was delivered in 10 fractions of 3.85 Gy (total equivalent dose (α/β = 3) — 52 Gy). In the APBI-HDR-BT group (n = 98), we delivered 8 fractions of 4 Gy over 4 days (two fractions per day with >6-hour intervals, total equivalent dose (α/β = 3) — 50 Gy). All patients met the GEC-ESTRO criteria for APBI. Cosmetic outcomes were assessed at 3 and 5 years post-treatment via a standardized telephone interview using six items from the BREAST-Q questionnaire. Responses were summed into a score (range: 6–18) and categorized as ‘excellent’, ‘good’, ‘satisfactory’, or ‘unsatisfactory’. Results : The median follow-up was 45 months in the APBI-EBRT group and 70 months in the APBI-HDR-BT group. The 3-year IBTR-FS was 100 % in both groups. The 3-year RFS was 97.6 % in the APBI-EBRT group and 98.0 % in the APBI-HDR-BT group (p = 1.0). In the APBI-HDR-BT group, the 5-year IBTR-FS and RFS rates were 95.1 % and 93.9 %, respectively. The 3-year cosmetic assessment revealed an ‘excellent’ result in 49 of 54 patients (90.7 %) in the APBI-EBRT group, while all 53 patients (100 %) in the APBI-HDR-BT group reported an ‘excellent’ result (p = 0.059). At the 5-year assessment, an ‘excellent’ cosmetic outcome was maintained in all patients in the APBI-HDR-BT group. Conclusion : Both APBI techniques (HDR-BT and EBRT) demonstrated comparably high efficacy in terms of local control after 3-year of follow-up. However, APBI delivered with HDR-BT showed a trend towards more favorable long-term cosmetic outcomes compared to APBI delivered with EBRT.
- 28 March 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (1)
Comparative Analysis of Oncological Efficacy and Cosmetic Outcomes of Accelerated Partial Breast Irradiation Techniques: Multicatheter Interstitial Brachytherapy and Conformal External Beam Radiotherapy
Accelerated partial breast irradiation (APBI) is a standard radiotherapy approach for patients with early-stage breast cancer. Various techniques can be employed to deliver APBI, with external beam radiotherapy (EBRT) and interstitial high-dose-rate brachytherapy (HDR-BT) using an Ir-192 source being the most commonly used in clinical practice. Purpose : To compare the oncological efficacy and cosmetic outcomes in breast cancer patients treated with postoperative APBI using either HDR-BT or EBRT. The primary efficacy endpoints were ipsilateral breast tumor recurrence-free survival (IBTR-FS) and recurrence-free survival (RFS). Materials and Methods : Between 2016 and 2022, 183 patients with рТ 1-2 N 0 M 0 breast cancer underwent APBI to the tumor bed after breast-conserving surgery. In the APBI-EBRT group (n = 85), irradiation was delivered in 10 fractions of 3.85 Gy (total equivalent dose (α/β = 3) — 52 Gy). In the APBI-HDR-BT group (n = 98), we delivered 8 fractions of 4 Gy over 4 days (two fractions per day with >6-hour intervals, total equivalent dose (α/β = 3) — 50 Gy). All patients met the GEC-ESTRO criteria for APBI. Cosmetic outcomes were assessed at 3 and 5 years post-treatment via a standardized telephone interview using six items from the BREAST-Q questionnaire. Responses were summed into a score (range: 6–18) and categorized as ‘excellent’, ‘good’, ‘satisfactory’, or ‘unsatisfactory’. Results : The median follow-up was 45 months in the APBI-EBRT group and 70 months in the APBI-HDR-BT group. The 3-year IBTR-FS was 100 % in both groups. The 3-year RFS was 97.6 % in the APBI-EBRT group and 98.0 % in the APBI-HDR-BT group (p = 1.0). In the APBI-HDR-BT group, the 5-year IBTR-FS and RFS rates were 95.1 % and 93.9 %, respectively. The 3-year cosmetic assessment revealed an ‘excellent’ result in 49 of 54 patients (90.7 %) in the APBI-EBRT group, while all 53 patients (100 %) in the APBI-HDR-BT group reported an ‘excellent’ result (p = 0.059). At the 5-year assessment, an ‘excellent’ cosmetic outcome was maintained in all patients in the APBI-HDR-BT group. Conclusion : Both APBI techniques (HDR-BT and EBRT) demonstrated comparably high efficacy in terms of local control after 3-year of follow-up. However, APBI delivered with HDR-BT showed a trend towards more favorable long-term cosmetic outcomes compared to APBI delivered with EBRT.
- 28 March 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (1)
Mammoscintigraphy in Patients with Aggressive Biological Subtypes of Breast Cancer: Assessment of Response to Neoadjuvant Chemotherapy
Purpose : To determine the diagnostic performance of mammoscintigraphy (SMG) with the 99m Tc-methoxy-isobutyl-isonitrile ( 99m Tc-MIBI) when used for assessment of the response to neoadjuvant chemotherapy (NACT) in patients with triple-negative and HER2-positive breast cancer (BC). Materials and methods : This retrospective study included 93 patients with morphologically verified triple-negative and HER2-positive breast cancer who received NACT between 2011 and 2018. Mammoscintigraphy was performed before treatment, after 2–3 and/or after 4–6 cycles of NACT. Diagnostic conclusions of SMG were compared with the results of morphological examination after surgical treatment at the end of NACT. The degree of pathological response to NACT was evaluated according to the Miller-Payne classification. Results : Overall, the sensitivity and specificity of SMG in predicting of complete pathologic tumor response after the completion of NACT were 83 % and 92 %, respectively. In patients with triple-negative and HER2-positive BC, sensitivity and specificity were 87 % and 92 %; 78 % and 91 %, respectively. When a complete scintigraphic response (grade V) was achieved after 2–3 cycles of NACT, the specificity and positive predictive value of SMG reached 100 % for both aggressive BC subtypes. Conclusions : The obtained results indicate the high diagnostic potential of SMG in predicting complete pathological tumor response to the NACT. Exceptional specificity and positive predictive value of SMG in the middle of the NACT make it promising tool in selection of BC patients for surgery de-escalation/elimination.
- 28 March 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (1)
Mammoscintigraphy in Patients with Aggressive Biological Subtypes of Breast Cancer: Assessment of Response to Neoadjuvant Chemotherapy
Purpose : To determine the diagnostic performance of mammoscintigraphy (SMG) with the 99m Tc-methoxy-isobutyl-isonitrile ( 99m Tc-MIBI) when used for assessment of the response to neoadjuvant chemotherapy (NACT) in patients with triple-negative and HER2-positive breast cancer (BC). Materials and methods : This retrospective study included 93 patients with morphologically verified triple-negative and HER2-positive breast cancer who received NACT between 2011 and 2018. Mammoscintigraphy was performed before treatment, after 2–3 and/or after 4–6 cycles of NACT. Diagnostic conclusions of SMG were compared with the results of morphological examination after surgical treatment at the end of NACT. The degree of pathological response to NACT was evaluated according to the Miller-Payne classification. Results : Overall, the sensitivity and specificity of SMG in predicting of complete pathologic tumor response after the completion of NACT were 83 % and 92 %, respectively. In patients with triple-negative and HER2-positive BC, sensitivity and specificity were 87 % and 92 %; 78 % and 91 %, respectively. When a complete scintigraphic response (grade V) was achieved after 2–3 cycles of NACT, the specificity and positive predictive value of SMG reached 100 % for both aggressive BC subtypes. Conclusions : The obtained results indicate the high diagnostic potential of SMG in predicting complete pathological tumor response to the NACT. Exceptional specificity and positive predictive value of SMG in the middle of the NACT make it promising tool in selection of BC patients for surgery de-escalation/elimination.
- Open Access
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 14-22
The impact of adjuvant radiotherapy on complications among who underwent delayed breast reconstruction
Background. Рostmastectomy radiation therapy (PMRT) is one of the causes of complications in patients with breast cancer after delayed breast reconstruction (DBR). Aim. To conduct a retrospective analysis of DBR outcomes and evaluate the impact of PMRT on the frequency and nature of complications. Materials and methods. Data from 178 patients with breast cancer who underwent DBR at N. N. Petrov National Medical Research Oncology Center, from 2015 to 2021 were included. In 87 patients, PMRT was administered to the soft tissues of the anterior chest wall and regional lymph nodes (group 1). Reconstruction with tissue expanders was performed in 66 (75.9 %), women while 1 (1.1 %) patient received a permanent implant. Six (6.9 %) patients underwent combined reconstruction using an expander with a thoraco-dorsal flap (TDF). In five (5.7 %) cases, a permanent implant was combined with TDF. Autologous reconstruction techniques were used in 10.3 % of cases (9 patients). Among the remaining 91 women PMRT was not performed (group 2). In this group, 69 (75.8 %) patients underwent reconstruction with tissue expanders, 2 (2.2 %) patients received permanent implants, 10 (11 %) patients had implants combined with TDF, and the combination of tissue expander with TDL was used in 2 (2.2 %) patients. Eight (8.8 %) patients underwent autologous reconstruction. Complications were assessed based on data from the medical information system “Vista” and telephone surveys and were determined as reconstructive failure (RF) and capsular contracture (CC) of Baker grades III–IV. Results. The mean follow-up duration was 48 months [14.5; 89.0] in the PMRT group and 63 months [38; 94] in the non-PMRT group. The overall complication rate was 27.5 % (49 cases), including reconstructive failures in 23 % (41 cases) and clinically significant СС (Baker III–IV) in 4.5 % (8 cases). RF occurred in 29.9 % of patients who received PMRT versus 16.5 % in those who did not (p = 0.03). The incidence of CC did not differ significantly: approximately 4.6 % in the PMRT group versus 4.4 % in the non-PMRT group (p = 0.95). Among patients who received PMRT after reconstruction with tissue expander RF were higher (33.3 %) compared to 14.5 % in non-irradiated patients (p = 0.01). Complications following autologous reconstruction occurred frequently regardless of PMRT status and probably were associated with the ability of surgery. Conclusion. Radiotherapy increases the risk of RF after DBR but was not associated with the risk of CC. Our data highlight the need to consider the impact of PMRT when planning DBR.
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 14-22
Open AccessThe impact of adjuvant radiotherapy on complications among who underwent delayed breast reconstruction
Background. Рostmastectomy radiation therapy (PMRT) is one of the causes of complications in patients with breast cancer after delayed breast reconstruction (DBR). Aim. To conduct a retrospective analysis of DBR outcomes and evaluate the impact of PMRT on the frequency and nature of complications. Materials and methods. Data from 178 patients with breast cancer who underwent DBR at N. N. Petrov National Medical Research Oncology Center, from 2015 to 2021 were included. In 87 patients, PMRT was administered to the soft tissues of the anterior chest wall and regional lymph nodes (group 1). Reconstruction with tissue expanders was performed in 66 (75.9 %), women while 1 (1.1 %) patient received a permanent implant. Six (6.9 %) patients underwent combined reconstruction using an expander with a thoraco-dorsal flap (TDF). In five (5.7 %) cases, a permanent implant was combined with TDF. Autologous reconstruction techniques were used in 10.3 % of cases (9 patients). Among the remaining 91 women PMRT was not performed (group 2). In this group, 69 (75.8 %) patients underwent reconstruction with tissue expanders, 2 (2.2 %) patients received permanent implants, 10 (11 %) patients had implants combined with TDF, and the combination of tissue expander with TDL was used in 2 (2.2 %) patients. Eight (8.8 %) patients underwent autologous reconstruction. Complications were assessed based on data from the medical information system “Vista” and telephone surveys and were determined as reconstructive failure (RF) and capsular contracture (CC) of Baker grades III–IV. Results. The mean follow-up duration was 48 months [14.5; 89.0] in the PMRT group and 63 months [38; 94] in the non-PMRT group. The overall complication rate was 27.5 % (49 cases), including reconstructive failures in 23 % (41 cases) and clinically significant СС (Baker III–IV) in 4.5 % (8 cases). RF occurred in 29.9 % of patients who received PMRT versus 16.5 % in those who did not (p = 0.03). The incidence of CC did not differ significantly: approximately 4.6 % in the PMRT group versus 4.4 % in the non-PMRT group (p = 0.95). Among patients who received PMRT after reconstruction with tissue expander RF were higher (33.3 %) compared to 14.5 % in non-irradiated patients (p = 0.01). Complications following autologous reconstruction occurred frequently regardless of PMRT status and probably were associated with the ability of surgery. Conclusion. Radiotherapy increases the risk of RF after DBR but was not associated with the risk of CC. Our data highlight the need to consider the impact of PMRT when planning DBR.
- Open Access
- 3 August 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (2) , 26-33
Assessment of the efficiency and safety of additional irradiation of the tumor bed using electrons or high-dose brachytherapy in patients with breast cancer
Aim. To evaluate the efficacy of interstitial high-dose rate brachytherapy (HDRB) or irradiation by electron as the methods for delivering boost to the tumor bed.Materials and methods. We performed a retrospective analysis of 5-year local control after whole breast irradiation and additional boost delivery to the tumor bed by HDRB or by electrons. In 485 breast cancer patients included in the analysis HDRB boost was performed in 247, by electrons – in another 238 women.Results. In 485 evaluated patients, local recurrences were diagnosed in 22 (4.5 %) cases: in 10 (4.0 %) of 247 women after HDRB boost and in 12 (5.0 %) of 238 patients who received a boost by electrons (р = 0.536). We found that age less than 50 years and aggressive subtypes (triple-negative, HER2+, luminal B HER2+) were associated with an increased risk of local recurrence (р = 0.003 and р = 0.004, respectively). The type of boost delivery (HDRB vs. electrons) does not influence the probability of local control in young women (р = 0.547) or in patients with aggressive subtypes of breast cancer. Conclusion. Both techniques of boost delivery (HDRB or electrons) are equally effective in prevention of local recurrence.
- 3 August 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (2) , 26-33
Open AccessAssessment of the efficiency and safety of additional irradiation of the tumor bed using electrons or high-dose brachytherapy in patients with breast cancer
Aim. To evaluate the efficacy of interstitial high-dose rate brachytherapy (HDRB) or irradiation by electron as the methods for delivering boost to the tumor bed.Materials and methods. We performed a retrospective analysis of 5-year local control after whole breast irradiation and additional boost delivery to the tumor bed by HDRB or by electrons. In 485 breast cancer patients included in the analysis HDRB boost was performed in 247, by electrons – in another 238 women.Results. In 485 evaluated patients, local recurrences were diagnosed in 22 (4.5 %) cases: in 10 (4.0 %) of 247 women after HDRB boost and in 12 (5.0 %) of 238 patients who received a boost by electrons (р = 0.536). We found that age less than 50 years and aggressive subtypes (triple-negative, HER2+, luminal B HER2+) were associated with an increased risk of local recurrence (р = 0.003 and р = 0.004, respectively). The type of boost delivery (HDRB vs. electrons) does not influence the probability of local control in young women (р = 0.547) or in patients with aggressive subtypes of breast cancer. Conclusion. Both techniques of boost delivery (HDRB or electrons) are equally effective in prevention of local recurrence.
- Open Access
- 12 January 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (6) , 22-31
Impact of dose fractionation regimen of adjuvant radiotherapy on cosmetic outcomes after immediate breast reconstruction
Background. Evidence for the safety of using the hypofractionation (HF) regimen after immediate breast reconstruction (IBR) in patients with breast cancer is not well documented. the purpose of the study was a retrospective analysis of surgical treatment with IBR and postoperative radiation therapy (RT) in conventional fractionated (CF) and hypofractionated (HF) regimens in breast cancer patients. Material and Methods. a retrospective analysis of treatment outcomes was carried out in 219 breast cancer patients who underwent mastectomy with IBR using permanent implant or tissue expander. all patients received postoperative RT: 97 received CF RT (22–25 fractions of 2 Gy) and 122 HF RT (15–16 fractions of 2.66–2.7 Gy). Cosmetic complications were represented by reconstructive failure (RF). all patients underwent an analysis of the incidence of reconstructive failures (RF) or capsular contracture (CC) (Baker III–IV). Results. CF RT was performed in 97 women: 55 – after IBR using tissue expander and 42 using permanent implant. the median follow-up time was 61 months. Complications were observed in 37 women (35.1 %): RF in 22 cases (22.7 %) and CC in 12 (12.4 %) cases. the median time to RF was 8 months, CC – 48.5 months. after RT to the tissue expander, CC rate was 0 %, RF – 25.5 %. after RT to the implants, CC was revealed in 28.6 %, RF in 19 % cases. In patients who received HF RT, cosmetic complications were detected in 51 (41.8 %) of 122 patients. the median follow-up time was 34 months. RF was revealed in 22.1 % cases, the median time was 9 months. CC was observed in 24 women (19.7 %) with the median time of 27 months. after HF RT to the expander, CC was observed in 4.9 %, RF in 39 % of cases. After RT to the implant, CC was detected in 27.2 %, RF in 13.6 % of cases. no significant differences in the risk of complication between patients who received conventional or hypofractionated RT were found (р=0.19). after RT to the expander, no differences (р=0.18 and р=0.12). After RT to the implant, there were also no differences in the frequency of CC and RF (р=0.52 and р=0.42). Conclusion. There were no significant differences in the frequency of cosmetic complications after postoperative radiotherapy in conventional fractionation or moderate hypofractionation regimens.
- 12 January 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (6) , 22-31
Open AccessImpact of dose fractionation regimen of adjuvant radiotherapy on cosmetic outcomes after immediate breast reconstruction
Background. Evidence for the safety of using the hypofractionation (HF) regimen after immediate breast reconstruction (IBR) in patients with breast cancer is not well documented. the purpose of the study was a retrospective analysis of surgical treatment with IBR and postoperative radiation therapy (RT) in conventional fractionated (CF) and hypofractionated (HF) regimens in breast cancer patients. Material and Methods. a retrospective analysis of treatment outcomes was carried out in 219 breast cancer patients who underwent mastectomy with IBR using permanent implant or tissue expander. all patients received postoperative RT: 97 received CF RT (22–25 fractions of 2 Gy) and 122 HF RT (15–16 fractions of 2.66–2.7 Gy). Cosmetic complications were represented by reconstructive failure (RF). all patients underwent an analysis of the incidence of reconstructive failures (RF) or capsular contracture (CC) (Baker III–IV). Results. CF RT was performed in 97 women: 55 – after IBR using tissue expander and 42 using permanent implant. the median follow-up time was 61 months. Complications were observed in 37 women (35.1 %): RF in 22 cases (22.7 %) and CC in 12 (12.4 %) cases. the median time to RF was 8 months, CC – 48.5 months. after RT to the tissue expander, CC rate was 0 %, RF – 25.5 %. after RT to the implants, CC was revealed in 28.6 %, RF in 19 % cases. In patients who received HF RT, cosmetic complications were detected in 51 (41.8 %) of 122 patients. the median follow-up time was 34 months. RF was revealed in 22.1 % cases, the median time was 9 months. CC was observed in 24 women (19.7 %) with the median time of 27 months. after HF RT to the expander, CC was observed in 4.9 %, RF in 39 % of cases. After RT to the implant, CC was detected in 27.2 %, RF in 13.6 % of cases. no significant differences in the risk of complication between patients who received conventional or hypofractionated RT were found (р=0.19). after RT to the expander, no differences (р=0.18 and р=0.12). After RT to the implant, there were also no differences in the frequency of CC and RF (р=0.52 and р=0.42). Conclusion. There were no significant differences in the frequency of cosmetic complications after postoperative radiotherapy in conventional fractionation or moderate hypofractionation regimens.
- 20 December 2024
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 16 (4) , 74-85
Capsular contracture in the modern era of combined breast cancer treatment: a multidisciplinary perspective on incidence and risk factors
BACKGROUND: Implant-based breast reconstruction in contrast to autologous reconstruction often requires revision surgery and ultimately leads to reconstructive failure, especially in adjuvant radiation therapy. Capsular contracture remains the most common complication leading to unsatisfactory aesthetic results. To date, there is no therapeutic target for the direct treatment of capsular contracture, which emphasizes the importance of its prevention. AIM: To determine the incidence and risk factors of capsular contracture in the era of multidisciplinary breast cancer treatment using modern surgical and therapeutic approaches. MATERIALS AND METHODS: The following retrospective study included 416 patients after mastectomy with immediate or delayed implant-based breast reconstruction in combination with adjuvant radiation therapy. Features of the surgical intervention, neoadjuvant and/or adjuvant systemic therapy were analyzed to determine the association with the risk of developing capsular contracture. RESULTS: Capsular contracture during alloplastic reconstructive plastic surgery with adjuvant radiation therapy, according to the literature, is a common complication with a complex and multifactorial pathogenesis. Despite the low incidence of capsular contracture III–IV Baker scale in the present study (7.7%, 32/416), the majority of patients required revision surgery (90.6%, 29/32). There was no correlation between risk of capsular contracture depending on the systemic treatment (z 1.96). CONCLUSIONS: The development of capsular contracture was significantly influenced by nipple-sparing mastectomy (13.7%, 22/167; z = 3.25) and the choice of periareolar access during surgery (29.6%, 13/44; z 1.96). Immediate one-stage reconstructions are associated with a significant number of capsular contractures (15.2%, 24/158; z 1.96), which statistically significantly depend on the subpectoral location of the endoprosthesis (22.1%, 21/95; z = 2.79) and choice of textured implants (20.8%, 22/106; z = 2.02).
- 20 December 2024
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 16 (4) , 74-85
Capsular contracture in the modern era of combined breast cancer treatment: a multidisciplinary perspective on incidence and risk factors
BACKGROUND: Implant-based breast reconstruction in contrast to autologous reconstruction often requires revision surgery and ultimately leads to reconstructive failure, especially in adjuvant radiation therapy. Capsular contracture remains the most common complication leading to unsatisfactory aesthetic results. To date, there is no therapeutic target for the direct treatment of capsular contracture, which emphasizes the importance of its prevention. AIM: To determine the incidence and risk factors of capsular contracture in the era of multidisciplinary breast cancer treatment using modern surgical and therapeutic approaches. MATERIALS AND METHODS: The following retrospective study included 416 patients after mastectomy with immediate or delayed implant-based breast reconstruction in combination with adjuvant radiation therapy. Features of the surgical intervention, neoadjuvant and/or adjuvant systemic therapy were analyzed to determine the association with the risk of developing capsular contracture. RESULTS: Capsular contracture during alloplastic reconstructive plastic surgery with adjuvant radiation therapy, according to the literature, is a common complication with a complex and multifactorial pathogenesis. Despite the low incidence of capsular contracture III–IV Baker scale in the present study (7.7%, 32/416), the majority of patients required revision surgery (90.6%, 29/32). There was no correlation between risk of capsular contracture depending on the systemic treatment (z 1.96). CONCLUSIONS: The development of capsular contracture was significantly influenced by nipple-sparing mastectomy (13.7%, 22/167; z = 3.25) and the choice of periareolar access during surgery (29.6%, 13/44; z 1.96). Immediate one-stage reconstructions are associated with a significant number of capsular contractures (15.2%, 24/158; z 1.96), which statistically significantly depend on the subpectoral location of the endoprosthesis (22.1%, 21/95; z = 2.79) and choice of textured implants (20.8%, 22/106; z = 2.02).
- Open Access
- 8 November 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (3) , 31-43
The role of local and systemic control methods in the treatment of oligometastatic breast cancer, taking into account biological subtypes (literature review)
Combined methods of treatment of oligometastatic breast cancer (OMBC) based on systemic drug treatment and local treatment methods - stereotactic radiation therapy (SRT) or surgical treatment - are not included in current clinical guidelines. The European Society of Medical Oncology (ESMO) recommends the use of local control methods for patients with breast cancer without taking into account the biological subtype of the tumor. This review presents a modern understanding of the oligometastatic biological subtype based on data from clinical studies on this topic, which could contribute to decision-making in real clinical practice.The aim of the review is analysis of the effectiveness of combined treatment methods: systemic drug therapy and local treatment methods (SRT) or surgical treatment of breast cancer of various molecular genetic subtypes.To assess the clinical effectiveness of various approaches to the treatment of breast cancer, depending on the biological subtype, a search was conducted for scientific publications in the Medline bibliographic database. Prospective and retrospective studies demonstrate an increase in the effectiveness of treatment through a combination of systemic therapy and local control methods (surgical treatment or SRT) OMBC depending on the biological subtypes. In hormonepositive breast cancer with bone damage, SRT is most preferable, whereas in visceral oligometastases, surgical treatment is recommended. For immunocompetent tumors of triple-negative and HER2-positive biological subtypes of breast cancer, surgical treatment of OMBC is not recommended, except in cases where the positive status of HER2 is combined with a high level of expression of hormonal receptors or metastatic bone damage.The results of current prospective studies focusing on certain biological subtypes of breast cancer will help further determine the role of this strategy in the treatment of this cohort of patients. Understanding the characteristics of the tumor process in breast cancer will allow you to personalize the treatment of patients with this disease.
- 8 November 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (3) , 31-43
Open AccessThe role of local and systemic control methods in the treatment of oligometastatic breast cancer, taking into account biological subtypes (literature review)
Combined methods of treatment of oligometastatic breast cancer (OMBC) based on systemic drug treatment and local treatment methods - stereotactic radiation therapy (SRT) or surgical treatment - are not included in current clinical guidelines. The European Society of Medical Oncology (ESMO) recommends the use of local control methods for patients with breast cancer without taking into account the biological subtype of the tumor. This review presents a modern understanding of the oligometastatic biological subtype based on data from clinical studies on this topic, which could contribute to decision-making in real clinical practice.The aim of the review is analysis of the effectiveness of combined treatment methods: systemic drug therapy and local treatment methods (SRT) or surgical treatment of breast cancer of various molecular genetic subtypes.To assess the clinical effectiveness of various approaches to the treatment of breast cancer, depending on the biological subtype, a search was conducted for scientific publications in the Medline bibliographic database. Prospective and retrospective studies demonstrate an increase in the effectiveness of treatment through a combination of systemic therapy and local control methods (surgical treatment or SRT) OMBC depending on the biological subtypes. In hormonepositive breast cancer with bone damage, SRT is most preferable, whereas in visceral oligometastases, surgical treatment is recommended. For immunocompetent tumors of triple-negative and HER2-positive biological subtypes of breast cancer, surgical treatment of OMBC is not recommended, except in cases where the positive status of HER2 is combined with a high level of expression of hormonal receptors or metastatic bone damage.The results of current prospective studies focusing on certain biological subtypes of breast cancer will help further determine the role of this strategy in the treatment of this cohort of patients. Understanding the characteristics of the tumor process in breast cancer will allow you to personalize the treatment of patients with this disease.
- Open Access
- 25 July 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (2) , 24-31
The impact of adjuvant radiotherapy for cosmetic results after immediate breast reconstruction based on the tissue expander and permanent implant
Background. One of the causes of complications in breast cancer patients after immediate breast reconstruction (IBR) is postmastectomy radiation therapy (PMRT).Aim. Retrospective analysis of the results of IBR, and evaluating the effect of PMRT on the frequency and type of complications.Materials and methods. Between 2015 and 2021, 798 patients underwent IBR with tissue expander or implant in N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia. PMRT was performed in 375 patients (group 1). The remaining 423 patients did not receive PMRT (group 2). Complications, including reconstructive failure (RF), Baker grade III/IV capsular contracture (CC), were recorded and analyzed.Results. Finally, cosmetic result analyzed in 521 patients. In 281 patients of PMRT group (group 1) IBR with expander or implant were performed in 144 and 137 cases, respectively. In the 240 patients without PMRT (group 2), IBR with expander was performed in 81 patients, with implant – in 159 cases. Pooled analysis revealed that overall rate of complications in the PMRT group was 33.8 % (in 95 of 281 patients), in non-irradiation patients – 22.9 % (in 55 of 240 patients), p 0.01. In group 1, RF were recorded in 67 (23.8 %) patients, in group 2 – in 44 (18.3 %) patients, p 0.05. CC in group 1 were detected in 28 (10 %) patients, in group 2 in 11 (4.6 %) patients, p 0.05. In patients with permanent implants RF were detected in 21 (14.6 %) of irradiation patients and in 22 (13.8 %) non-irradiation patients (p 0.2). On the contrary, CC were mentioned in 22 (16.1 %) of irradiated patient and in 8 (5 %) patients that didn’t receive PMRT, p 0.005. After reconstruction with expander RF were diagnosed in 46 (31.9 %) patients after PMRT and in 22 (27.2 %) non-irradiation patients, p 0.2. CC were observed in 6 (4.2 %) patients from PMRT group and in 3 (3.7 %) patients treated without PMRT, p 0.2.Conclusion. PMRT in patients after IBR with simultaneous installation of a permanent implant is characterized by a decrease in the incidence of RF, but an increase in the incidence of CC.
- 25 July 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (2) , 24-31
Open AccessThe impact of adjuvant radiotherapy for cosmetic results after immediate breast reconstruction based on the tissue expander and permanent implant
Background. One of the causes of complications in breast cancer patients after immediate breast reconstruction (IBR) is postmastectomy radiation therapy (PMRT).Aim. Retrospective analysis of the results of IBR, and evaluating the effect of PMRT on the frequency and type of complications.Materials and methods. Between 2015 and 2021, 798 patients underwent IBR with tissue expander or implant in N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia. PMRT was performed in 375 patients (group 1). The remaining 423 patients did not receive PMRT (group 2). Complications, including reconstructive failure (RF), Baker grade III/IV capsular contracture (CC), were recorded and analyzed.Results. Finally, cosmetic result analyzed in 521 patients. In 281 patients of PMRT group (group 1) IBR with expander or implant were performed in 144 and 137 cases, respectively. In the 240 patients without PMRT (group 2), IBR with expander was performed in 81 patients, with implant – in 159 cases. Pooled analysis revealed that overall rate of complications in the PMRT group was 33.8 % (in 95 of 281 patients), in non-irradiation patients – 22.9 % (in 55 of 240 patients), p 0.01. In group 1, RF were recorded in 67 (23.8 %) patients, in group 2 – in 44 (18.3 %) patients, p 0.05. CC in group 1 were detected in 28 (10 %) patients, in group 2 in 11 (4.6 %) patients, p 0.05. In patients with permanent implants RF were detected in 21 (14.6 %) of irradiation patients and in 22 (13.8 %) non-irradiation patients (p 0.2). On the contrary, CC were mentioned in 22 (16.1 %) of irradiated patient and in 8 (5 %) patients that didn’t receive PMRT, p 0.005. After reconstruction with expander RF were diagnosed in 46 (31.9 %) patients after PMRT and in 22 (27.2 %) non-irradiation patients, p 0.2. CC were observed in 6 (4.2 %) patients from PMRT group and in 3 (3.7 %) patients treated without PMRT, p 0.2.Conclusion. PMRT in patients after IBR with simultaneous installation of a permanent implant is characterized by a decrease in the incidence of RF, but an increase in the incidence of CC.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (3)
Reconstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reconstruction failure
Background. Breast reconstruction after mastectomy must consider potential complications from surgical techniques as well as additional complications that may arise from oncologic treatment steps such as radiation or systemic therapy. But the consensus is lacking regarding the optimal reconstruction plan for patients requiring adjuvant radiation therapy. Objective. To determine the impact of risk factors on the development complications of breast reconstruction for postmastectomy radiotherapy. Material and methods. This study included patients diagnosed with breast cancer who received combination treatment from 2016 to 2021 at the N.N. Petrov National Medical Research Center of Oncology. The patients were divided into 3 groups: immediate reconstruction (158 people), immediate-delayed (210 people) and delayed (98 people). Results. Every fourth patient (24.0%, 112/466) may encounter a complication after mastectomy with reconstruction and adjuvant radiation therapy. According to the analyzed data, there was no correlation between potential risk factors depending on the general status of patients (age, obesity, diabetes mellitus, hypertension, history of smoking) and the occurrence of complications after combination treatment. Conclusion. The analysis of complications and reconstructive failures showed that immediate breast reconstruction at the N.N. Petrov National Medical Research Center of Oncology is the safest method of reconstruction in the combined treatment of breast cancer with the lowest incidence of severe complications, which plays a key role in the development of reconstructive failures. However, these surgeries are associated with a significant number of capsular contractures, which requires finding ways to minimize these risks to optimize treatment in each individual case in short and long term.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (3)
Reconstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reconstruction failure
Background. Breast reconstruction after mastectomy must consider potential complications from surgical techniques as well as additional complications that may arise from oncologic treatment steps such as radiation or systemic therapy. But the consensus is lacking regarding the optimal reconstruction plan for patients requiring adjuvant radiation therapy. Objective. To determine the impact of risk factors on the development complications of breast reconstruction for postmastectomy radiotherapy. Material and methods. This study included patients diagnosed with breast cancer who received combination treatment from 2016 to 2021 at the N.N. Petrov National Medical Research Center of Oncology. The patients were divided into 3 groups: immediate reconstruction (158 people), immediate-delayed (210 people) and delayed (98 people). Results. Every fourth patient (24.0%, 112/466) may encounter a complication after mastectomy with reconstruction and adjuvant radiation therapy. According to the analyzed data, there was no correlation between potential risk factors depending on the general status of patients (age, obesity, diabetes mellitus, hypertension, history of smoking) and the occurrence of complications after combination treatment. Conclusion. The analysis of complications and reconstructive failures showed that immediate breast reconstruction at the N.N. Petrov National Medical Research Center of Oncology is the safest method of reconstruction in the combined treatment of breast cancer with the lowest incidence of severe complications, which plays a key role in the development of reconstructive failures. However, these surgeries are associated with a significant number of capsular contractures, which requires finding ways to minimize these risks to optimize treatment in each individual case in short and long term.
- Open Access
- 26 March 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 183 (1) , 42-46
Surgical tactics for esophageal cancer with complete pathomorphosis after chemoradiotherapy
Esophageal cancer is an oncological disease with a poor prognosis due to late diagnosis and detection of the tumor at a late stage. At present, the combined method of treatment is generally accepted for this pathology, starting from stage IIA. Preoperative chemoradiation therapy in this approach helps to achieve not only partial but also complete regression of the tumor. The question of the necessity of surgical tactics in this group of patients, due to the lack of clear recommendations, remains controversial at present. The article presents a successful case of neoadjuvant chemoradiation therapy, which made it possible to achieve not only clinical, but also complete pathomorphological regression of the tumor. This tumor response to chemoradiation therapy occurs in less than a third of all patients with esophageal cancer. Despite this, complete regression of the tumor does not mean recovery.
- 26 March 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 183 (1) , 42-46
Open AccessSurgical tactics for esophageal cancer with complete pathomorphosis after chemoradiotherapy
Esophageal cancer is an oncological disease with a poor prognosis due to late diagnosis and detection of the tumor at a late stage. At present, the combined method of treatment is generally accepted for this pathology, starting from stage IIA. Preoperative chemoradiation therapy in this approach helps to achieve not only partial but also complete regression of the tumor. The question of the necessity of surgical tactics in this group of patients, due to the lack of clear recommendations, remains controversial at present. The article presents a successful case of neoadjuvant chemoradiation therapy, which made it possible to achieve not only clinical, but also complete pathomorphological regression of the tumor. This tumor response to chemoradiation therapy occurs in less than a third of all patients with esophageal cancer. Despite this, complete regression of the tumor does not mean recovery.